[go: up one dir, main page]

ES2572368T3 - Tratamiento de la artrosis - Google Patents

Tratamiento de la artrosis

Info

Publication number
ES2572368T3
ES2572368T3 ES09833924T ES09833924T ES2572368T3 ES 2572368 T3 ES2572368 T3 ES 2572368T3 ES 09833924 T ES09833924 T ES 09833924T ES 09833924 T ES09833924 T ES 09833924T ES 2572368 T3 ES2572368 T3 ES 2572368T3
Authority
ES
Spain
Prior art keywords
osteoarthritis treatment
osteoarthritis
treatment
antagonist
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09833924T
Other languages
English (en)
Other versions
ES2572368T5 (es
Inventor
John Allan Hamilton
Andrew David Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2572368(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Melbourne filed Critical University of Melbourne
Application granted granted Critical
Publication of ES2572368T3 publication Critical patent/ES2572368T3/es
Publication of ES2572368T5 publication Critical patent/ES2572368T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un antagonista de GM-CSF para su uso en el tratamiento de artrosis, en el que el antagonista es un anticuerpo específico de GM-CSF.
ES09833924T 2008-12-22 2009-12-21 Tratamiento de la artrosis Active ES2572368T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (2)

Publication Number Publication Date
ES2572368T3 true ES2572368T3 (es) 2016-05-31
ES2572368T5 ES2572368T5 (es) 2021-12-16

Family

ID=42286786

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09833924T Active ES2572368T5 (es) 2008-12-22 2009-12-21 Tratamiento de la artrosis
ES15194091T Active ES2886063T3 (es) 2008-12-22 2009-12-21 Tratamiento de la artrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15194091T Active ES2886063T3 (es) 2008-12-22 2009-12-21 Tratamiento de la artrosis

Country Status (19)

Country Link
US (4) US9243061B2 (es)
EP (2) EP3056217B1 (es)
JP (3) JP5727379B2 (es)
KR (2) KR101799264B1 (es)
CN (2) CN106397591A (es)
AU (1) AU2009329814B2 (es)
BR (1) BRPI0918356B1 (es)
CA (1) CA2746827C (es)
CY (1) CY1117698T1 (es)
DK (1) DK2376121T4 (es)
ES (2) ES2572368T5 (es)
HK (1) HK1226938A1 (es)
HR (1) HRP20160577T4 (es)
HU (1) HUE028615T2 (es)
PL (1) PL2376121T5 (es)
RU (2) RU2011127334A (es)
SI (2) SI2376121T1 (es)
SM (1) SMT201600156B (es)
WO (1) WO2010071924A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011127334A (ru) * 2008-12-22 2013-01-27 Де Юниверсити Оф Мельбурн Лечение остеоартрита
EP2387418B1 (en) 2008-12-22 2018-06-13 The University of Melbourne Pain treatment
HK1208231A1 (en) 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods of treatment of osteoarthritis with transdermal cannabidiol gel
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL95061A0 (en) 1989-07-14 1991-06-10 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US20060067938A1 (en) * 2001-10-26 2006-03-30 Sherif Daouti Methods for the treatment of osteoarthritis and compositions thereof
AU2003217386B2 (en) 2002-02-13 2008-06-26 Ludwig Institute For Cancer Research Humanized GM-CSF antibodies
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
BRPI0506679A (pt) † 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
CA2561530C (en) * 2004-03-31 2014-04-22 Kazuwa Nakao Therapeutic or prophylactic agent for arthritis
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
US7662573B2 (en) * 2004-08-18 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Methods for evaluating osteoarthritis risk
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
HUE025134T2 (en) 2005-04-18 2016-01-28 Amgen Res Munich Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
HRP20150023T1 (hr) * 2005-05-18 2015-02-27 Morphosys Ag Protutijela protiv gm-csf i njihova upotreba
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
DK1981909T3 (en) * 2006-02-08 2017-01-23 Morphotek Inc Antigenic GM¸]CSF¸]peptides and antibodies against GM¸]CSF
EP2423230B1 (en) * 2006-03-27 2013-05-08 Medimmune Limited Binding member for GM-CSF receptor
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US7879856B2 (en) * 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
MX2010005291A (es) * 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
WO2009118662A2 (en) † 2008-03-24 2009-10-01 Abbott Biotechnology Ltd. Methods and compositions for treating bone loss
JP5688363B2 (ja) 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
EP2387418B1 (en) † 2008-12-22 2018-06-13 The University of Melbourne Pain treatment
RU2011127334A (ru) 2008-12-22 2013-01-27 Де Юниверсити Оф Мельбурн Лечение остеоартрита
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Also Published As

Publication number Publication date
US20200247895A1 (en) 2020-08-06
US20180066062A1 (en) 2018-03-08
RU2016102339A (ru) 2018-11-21
KR101898982B1 (ko) 2018-09-14
BRPI0918356A2 (pt) 2020-10-06
JP2015143233A (ja) 2015-08-06
EP2376121A1 (en) 2011-10-19
CN102271705A (zh) 2011-12-07
AU2009329814A1 (en) 2010-07-01
JP2017200933A (ja) 2017-11-09
EP2376121B2 (en) 2021-06-09
AU2009329814B2 (en) 2015-06-18
JP6458086B2 (ja) 2019-01-23
KR20170128630A (ko) 2017-11-22
RU2712273C2 (ru) 2020-01-28
HK1226938A1 (en) 2017-10-13
JP2012512815A (ja) 2012-06-07
CN106397591A (zh) 2017-02-15
ES2572368T5 (es) 2021-12-16
PL2376121T5 (pl) 2021-09-27
DK2376121T4 (da) 2021-08-16
SI2376121T1 (sl) 2016-07-29
HRP20160577T4 (hr) 2021-08-20
CY1117698T1 (el) 2017-05-17
KR20110128273A (ko) 2011-11-29
RU2016102339A3 (es) 2019-07-29
DK2376121T3 (en) 2016-05-30
US9243061B2 (en) 2016-01-26
EP3056217B1 (en) 2021-06-30
KR101799264B1 (ko) 2017-11-20
HUE028615T2 (en) 2016-12-28
US20120003234A1 (en) 2012-01-05
RU2011127334A (ru) 2013-01-27
EP3056217A1 (en) 2016-08-17
EP2376121B1 (en) 2016-03-09
EP2376121A4 (en) 2013-04-03
WO2010071924A1 (en) 2010-07-01
SI2376121T2 (sl) 2021-11-30
PL2376121T3 (pl) 2016-12-30
CA2746827C (en) 2018-01-23
CA2746827A1 (en) 2010-07-01
HRP20160577T1 (hr) 2016-07-29
US20160185868A1 (en) 2016-06-30
SMT201600156B (it) 2016-08-31
ES2886063T3 (es) 2021-12-16
JP5727379B2 (ja) 2015-06-03
BRPI0918356B1 (pt) 2022-03-08

Similar Documents

Publication Publication Date Title
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2009001263S1 (es) Maquina de afeitar.
CR11776A (es) Inhibidores de bace
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
BR112013028422A2 (pt) ativadores de piruvato cinase para uso em terapia
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
UY33124A (es) Agentes y epítopos enlazados a wise
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
CL2011000562A1 (es) Compuesto derivado de tetraciclina; util en el tratamiento de artritis reumatoide.
BRPI0923291A2 (pt) processo para a destilação de uma mistura aquosa de polimetilol, composição, e, uso de um polimetilol.
CL2009001363S1 (es) Pieza para maquina de afeitar.
ES2572368T3 (es) Tratamiento de la artrosis
CU20130044A7 (es) Proceso para la preparación de inhibidores de pan-cdk de fórmula (i), e intermediarios de la preparación
MX2015003039A (es) Proceso para la reducción de derivados nitro a aminas.
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.
CL2010001344S1 (es) Urinario quimico para cuatro usuarios simultaneos.
CL2009000054S1 (es) Frasco para cosmeticos.